Gliomas with IDH mutations (IDH-mutant) are generally associated with more favorable clinical outcomes and prolonged survival compared to IDH-wildtype gliomas, which tend to be more aggressive and confer a worse prognosis [2]. The gene discussed is IDH2; the disease is central nervous system cancer.